JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
17/12/24 - 12:56
2025 Annual Calendar of Corporate Events (104.79 KB)
11/11/24 - 7:38
Diasorin Announces 510(k) Submission for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX® (122.52 KB)
05/11/24 - 16:27
Diasorin reports another quarter with Revenues and Profitability in expansion, raising the Full-Year 2024 Revenue Guidance (238.01 KB)
27/09/24 - 7:35
Diasorin announces 510(k) submission for LIAISON PLEX® Gram-Negative Blood Culture Assay (559.45 KB)
09/09/24 - 13:11
Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)
05/09/24 - 11:17
DiaSorin S.p.A. - Update 2024 Annual Calendar of Corporate Events (99.93 KB)
04/09/24 - 11:36
Diasorin S.p.A. - Shareholders' Meeting September 4, 2024 (136.09 KB)
29/07/24 - 15:55
DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)
16/07/24 - 8:31
Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)
05/06/24 - 5:07
Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)
16/05/24 - 19:56
Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)
10/05/24 - 15:21
Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)
24/04/24 - 15:38
Shareholders' Meeting 2024 (159.72 KB)
16/04/24 - 8:20
Communication on total amount of voting rights (135.47 KB)
15/03/24 - 13:35
The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)
13/03/24 - 10:23
Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)
03/03/24 - 19:32
Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)
25/01/24 - 7:48
Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)
19/12/16 - 10:00
Co-optation of a Director (333.18 KB)
10/11/16 - 1:00
DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016 (1.05 MB)
02/11/16 - 1:00
DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST (141.53 KB)
30/08/16 - 2:00
DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market (404.63 KB)
22/08/16 - 2:00
DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY (158.39 KB)
04/08/16 - 2:00
The Board of Directors approves results for H1'16 (697.16 KB)
28/07/16 - 2:00
DiaSorin starts selling Vitamin D in Japan (724.4 KB)
14/07/16 - 2:00
DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia (278.18 KB)
10/06/16 - 2:00
Weekly report treasury shares buy-back (289.83 KB)
10/06/16 - 2:00
Conclusion buy-back plan (367.77 KB)
07/06/16 - 2:00
DiaSorin launches the new Helicobacter pylori IgG CLIA test (518.61 KB)
03/06/16 - 2:00
Weekly report treasury shares buy-back (290.21 KB)
30/05/16 - 2:00
Notice filing By-Laws and publication operating procedures for loyalty shares (277.79 KB)
27/05/16 - 2:00
Weekly report treasury shares buy-back (289.34 KB)
20/05/16 - 2:00
Weekly report treasury shares buy-back (290.09 KB)
13/05/16 - 2:00
Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business (350.22 KB)
12/05/16 - 2:00
Start up treasury shares buy-back plan (305.9 KB)
09/05/16 - 2:00
The Board of Directors approves the results for Q1'16 (632.78 KB)
28/04/16 - 2:00
Shareholders' Meeting FY 2015 (365.15 KB)
30/03/16 - 2:00
DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business (133.62 KB)
09/03/16 - 1:00